Epithelial–Mesenchymal Transition Suppresses AMPK and Sensitizes Cancer Cells to Pyroptosis under Energy Stress

Epithelial–mesenchymal transition (EMT) is implicated in tumor metastasis and therapeutic resistance. It remains a challenge to target cancer cells that have undergone EMT. The Snail family of key EMT-inducing transcription factors directly binds to and transcriptionally represses not only epithelial genes but also a myriad of additional genomic targets that may carry out significant biological functions. Therefore, we reasoned that EMT inherently causes various concomitant phenotypes, some of which may create targetable vulnerabilities for cancer treatment. In the present study, we found that Snail transcription factors bind to the promoters of multiple genes encoding subunits of the AMP-activated protein kinase (AMPK) complex, and expression of AMPK genes was markedly downregulated by EMT. Accordingly, high AMPK expression in tumors correlated with epithelial cell markers and low AMPK expression in tumors was strongly associated with adverse prognosis. AMPK is the principal sensor of cellular energy status. In response to energy stress, AMPK is activated and critically reprograms cellular metabolism to restore energy homeostasis and maintain cell survival. We showed that activation of AMPK by energy stress was severely impaired by EMT. Consequently, EMT cancer cells became hypersensitive to a variety of energy stress conditions and primarily underwent pyroptosis, a regulated form of necrotic cell death. Collectively, the study suggests that EMT impedes the activation of AMPK signaling induced by energy stress and sensitizes cancer cells to pyroptotic cell death under energy stress conditions. Therefore, while EMT promotes malignant progression, it concurrently induces collateral vulnerabilities that may be therapeutically exploited.

[1]  Bingshu E. Chen,et al.  Effect of Metformin vs Placebo on Invasive Disease-Free Survival in Patients With Breast Cancer: The MA.32 Randomized Clinical Trial. , 2022, JAMA.

[2]  G. Christofori,et al.  Distinct contributions of partial and full EMT to breast cancer malignancy. , 2021, Developmental cell.

[3]  Masafumi Takahashi,et al.  Loop Between NLRP3 Inflammasome and Reactive Oxygen Species. , 2021, Antioxidants & redox signaling.

[4]  John G Doench,et al.  Control of gasdermin D oligomerization and pyroptosis by the Ragulator-Rag-mTORC1 pathway , 2021, Cell.

[5]  S. Cai,et al.  Metformin Adjunct With Antineoplastic Agents for the Treatment of Lung Cancer: A Meta-Analysis of Randomized Controlled Trials and Observational Cohort Studies , 2021, Frontiers in Pharmacology.

[6]  Beth K. Martin,et al.  Single-cell lineage tracing of metastatic cancer reveals selection of hybrid EMT states. , 2021, Cancer cell.

[7]  N. Matsumura,et al.  Tumor Immune Microenvironment during Epithelial–Mesenchymal Transition , 2021, Clinical Cancer Research.

[8]  D. Hardie,et al.  AMP-Activated Protein Kinase: Do We Need Activators or Inhibitors to Treat or Prevent Cancer? , 2020, International journal of molecular sciences.

[9]  A. Strasser,et al.  Emerging connectivity of programmed cell death pathways and its physiological implications , 2020, Nature Reviews Molecular Cell Biology.

[10]  Tao Yu,et al.  NLRP3 inflammasome in endothelial dysfunction , 2020, Cell Death & Disease.

[11]  B. Vanderhyden,et al.  Context specificity of the EMT transcriptional response , 2020, Nature Communications.

[12]  Kristen Fousek,et al.  Tumor Plasticity and Resistance to Immunotherapy. , 2020, Trends in cancer.

[13]  J. Lieberman,et al.  FDA-approved disulfiram inhibits pyroptosis by blocking gasdermin D pore formation , 2020, Nature Immunology.

[14]  Z. Xiao,et al.  Transcriptional suppression of AMPKα1 promotes breast cancer metastasis upon oncogene activation , 2020, Proceedings of the National Academy of Sciences.

[15]  Y. Ruan,et al.  LATS kinase–mediated CTCF phosphorylation and selective loss of genomic binding , 2020, Science Advances.

[16]  Hao Wu,et al.  TRPM2, linking oxidative stress and Ca2+ permeation to NLRP3 inflammasome activation. , 2020, Current opinion in immunology.

[17]  Jitendra Kumar Meena,et al.  Energy stress-mediated AMPK activation inhibits ferroptosis , 2020, Nature Cell Biology.

[18]  A. Jaśkiewicz,et al.  2-Deoxy-d-Glucose and Its Analogs: From Diagnostic to Therapeutic Agents , 2019, International journal of molecular sciences.

[19]  D. Cescon,et al.  A phase II randomized clinical trial of the effect of metformin versus placebo on progression-free survival in women with metastatic breast cancer receiving standard chemotherapy. , 2019, Breast.

[20]  F. Shao,et al.  The gasdermins, a protein family executing cell death and inflammation , 2019, Nature Reviews Immunology.

[21]  Arnaud J. Legrand,et al.  The Diversification of Cell Death and Immunity: Memento Mori. , 2019, Molecular cell.

[22]  Luca Mazzarella,et al.  Combination of Hypoglycemia and Metformin Impairs Tumor Metabolic Plasticity and Growth by Modulating the PP2A-GSK3β-MCL-1 Axis. , 2019, Cancer cell.

[23]  Han-Ming Shen,et al.  Critical role of AMPK in redox regulation under glucose starvation , 2019, Redox biology.

[24]  P. Gutin,et al.  Gboxin is an oxidative phosphorylation inhibitor that targets glioblastoma , 2019, Nature.

[25]  Y. Ishikawa,et al.  Epithelial-to-Mesenchymal Transition Is a Mechanism of ALK Inhibitor Resistance in Lung Cancer Independent of ALK Mutation Status. , 2019, Cancer research.

[26]  Piyush B. Gupta,et al.  Phenotypic Plasticity: Driver of Cancer Initiation, Progression, and Therapy Resistance. , 2019, Cell stem cell.

[27]  T. Brabletz,et al.  Non-redundant functions of EMT transcription factors , 2019, Nature Cell Biology.

[28]  X. Fang,et al.  Ovarian Cancer Relies on Glucose Transporter 1 to Fuel Glycolysis and Growth: Anti-Tumor Activity of BAY-876 , 2018, Cancers.

[29]  O. Nanni,et al.  Metformin plus chemotherapy versus chemotherapy alone in the first-line treatment of HER2-negative metastatic breast cancer. The MYME randomized, phase 2 clinical trial , 2018, Breast Cancer Research and Treatment.

[30]  M. Protopopova,et al.  An inhibitor of oxidative phosphorylation exploits cancer vulnerability , 2018, Nature Medicine.

[31]  Johan Hartman,et al.  Chemoresistance Evolution in Triple-Negative Breast Cancer Delineated by Single-Cell Sequencing , 2018, Cell.

[32]  T. Voet,et al.  Identification of the tumour transition states occurring during EMT , 2018, Nature.

[33]  P. Agostinis,et al.  Cell death and immunity in cancer: From danger signals to mimicry of pathogen defense responses , 2017, Immunological reviews.

[34]  Wen Bu,et al.  Breast tumor cell-specific knockout of Twist1 inhibits cancer cell plasticity, dissemination, and lung metastasis in mice , 2017, Proceedings of the National Academy of Sciences.

[35]  S. Zhang,et al.  A randomized phase II study of aromatase inhibitors plus metformin in pre-treated postmenopausal patients with hormone receptor positive metastatic breast cancer , 2017, Oncotarget.

[36]  Jill P. Mesirov,et al.  Dependency of a therapy-resistant state of cancer cells on a lipid peroxidase pathway , 2017, Nature.

[37]  Stuart L. Schreiber,et al.  Drug-tolerant persister cancer cells are vulnerable to GPX4 inhibition , 2017, Nature.

[38]  R. Shaw,et al.  AMPK: Mechanisms of Cellular Energy Sensing and Restoration of Metabolic Balance. , 2017, Molecular cell.

[39]  C. Pilarsky,et al.  The EMT-activator Zeb1 is a key factor for cell plasticity and promotes metastasis in pancreatic cancer , 2017, Nature Cell Biology.

[40]  D. Bachovchin,et al.  Pyroptosis and Apoptosis Pathways Engage in Bidirectional Crosstalk in Monocytes and Macrophages. , 2017, Cell chemical biology.

[41]  Matthew L. Albert,et al.  Dying cells actively regulate adaptive immune responses , 2017, Nature Reviews Immunology.

[42]  L. Chin,et al.  Synthetic vulnerabilities of mesenchymal subpopulations in pancreatic cancer , 2017, Nature.

[43]  Binbin Xie,et al.  Glucose transporter GLUT1 expression and clinical outcome in solid tumors: a systematic review and meta-analysis , 2017, Oncotarget.

[44]  Lung-Ji Chang,et al.  Epithelial-to-mesenchymal transition confers pericyte properties on cancer cells. , 2016, The Journal of clinical investigation.

[45]  T. Müller,et al.  Identification and Optimization of the First Highly Selective GLUT1 Inhibitor BAY‐876 , 2016, ChemMedChem.

[46]  G. Stassi,et al.  Epithelial–mesenchymal transition: a new target in anticancer drug discovery , 2016, Nature Reviews Drug Discovery.

[47]  A. Brunet,et al.  AMPK: An Energy-Sensing Pathway with Multiple Inputs and Outputs. , 2016, Trends in cell biology.

[48]  Jean Paul Thiery,et al.  EMT: 2016 , 2016, Cell.

[49]  Roberto Bianco,et al.  Mechanisms of lapatinib resistance in HER2-driven breast cancer. , 2015, Cancer treatment reviews.

[50]  Stephen T. C. Wong,et al.  EMT is not required for lung metastasis but contributes to chemoresistance , 2015, Nature.

[51]  V. LeBleu,et al.  EMT Program is Dispensable for Metastasis but Induces Chemoresistance in Pancreatic Cancer , 2015, Nature.

[52]  R. Chapple,et al.  AMPK Protects Leukemia-Initiating Cells in Myeloid Leukemias from Metabolic Stress in the Bone Marrow. , 2015, Cell stem cell.

[53]  R. Weinberg,et al.  Distinct EMT programs control normal mammary stem cells and tumour-initiating cells , 2015, Nature.

[54]  Michael J. Ziller,et al.  Transcription factor binding dynamics during human ESC differentiation , 2015, Nature.

[55]  A. Morris,et al.  Metformin in cancer treatment and prevention. , 2015, Annual review of medicine.

[56]  B. Viollet,et al.  Metformin: from mechanisms of action to therapies. , 2014, Cell metabolism.

[57]  Ying Wang,et al.  SNAI2 Controls the Undifferentiated State of Human Epidermal Progenitor Cells , 2014, Stem cells.

[58]  G. Longmore,et al.  Transient SNAIL1 expression is necessary for metastatic competence in breast cancer. , 2014, Cancer research.

[59]  Lorenzo Galluzzi,et al.  Metabolic control of cell death , 2014, Science.

[60]  V. Natarajan,et al.  Reactive oxygen species at the crossroads of inflammasome and inflammation , 2014, Front. Physiol..

[61]  Samy Lamouille,et al.  Molecular mechanisms of epithelial–mesenchymal transition , 2014, Nature Reviews Molecular Cell Biology.

[62]  Jan Budczies,et al.  Online Survival Analysis Software to Assess the Prognostic Value of Biomarkers Using Transcriptomic Data in Non-Small-Cell Lung Cancer , 2013, PloS one.

[63]  G. Mills,et al.  AMPK: a contextual oncogene or tumor suppressor? , 2013, Cancer research.

[64]  Liu Wei,et al.  LKB1 inactivation dictates therapeutic response of non-small cell lung cancer to the metabolism drug phenformin. , 2013, Cancer cell.

[65]  B. Law,et al.  An in vivo model of epithelial to mesenchymal transition reveals a mitogenic switch. , 2012, Cancer letters.

[66]  Jing Yang,et al.  Spatiotemporal regulation of epithelial-mesenchymal transition is essential for squamous cell carcinoma metastasis. , 2012, Cancer cell.

[67]  Michael Peyton,et al.  An Epithelial–Mesenchymal Transition Gene Signature Predicts Resistance to EGFR and PI3K Inhibitors and Identifies Axl as a Therapeutic Target for Overcoming EGFR Inhibitor Resistance , 2012, Clinical Cancer Research.

[68]  C. Thornton,et al.  AMP-activated protein kinase: new regulation, new roles? , 2012, The Biochemical journal.

[69]  Jae Cheol Lee,et al.  Activation of the AXL Kinase Causes Resistance to EGFR-Targeted Therapy in Lung Cancer , 2012, Nature Genetics.

[70]  Navdeep S. Chandel,et al.  AMPK regulates NADPH homeostasis to promote tumour cell survival during energy stress , 2012, Nature.

[71]  M. R. Lamprecht,et al.  Ferroptosis: An Iron-Dependent Form of Nonapoptotic Cell Death , 2012, Cell.

[72]  D. Hardie,et al.  AMPK: a nutrient and energy sensor that maintains energy homeostasis , 2012, Nature Reviews Molecular Cell Biology.

[73]  Jennifer B Dennison,et al.  Dual Inhibition of Tumor Energy Pathway by 2-Deoxyglucose and Metformin Is Effective against a Broad Spectrum of Preclinical Cancer Models , 2011, Molecular Cancer Therapeutics.

[74]  C. Lee,et al.  Clinical and molecular evidences of epithelial to mesenchymal transition in acquired resistance to EGFR-TKIs. , 2011, Lung cancer.

[75]  S. Digumarthy,et al.  Genotypic and Histological Evolution of Lung Cancers Acquiring Resistance to EGFR Inhibitors , 2011, Science Translational Medicine.

[76]  T. Oyama,et al.  Epithelial-mesenchymal transition in EGFR-TKI acquired resistant lung adenocarcinoma. , 2010, Anticancer research.

[77]  C. Bertolotto,et al.  Targeting cancer cell metabolism: the combination of metformin and 2-deoxyglucose induces p53-dependent apoptosis in prostate cancer cells. , 2010, Cancer research.

[78]  Jeffrey M. Rosen,et al.  Residual breast cancers after conventional therapy display mesenchymal as well as tumor-initiating features , 2009, Proceedings of the National Academy of Sciences.

[79]  A. Look,et al.  Slug Antagonizes p53-Mediated Apoptosis of Hematopoietic Progenitors by Repressing puma , 2005, Cell.

[80]  R. Sabirov,et al.  Cells die with increased cytosolic ATP during apoptosis: a bioluminescence study with intracellular luciferase , 2005, Cell Death and Differentiation.

[81]  Robert D Cardiff,et al.  The transcriptional repressor Snail promotes mammary tumor recurrence. , 2005, Cancer cell.

[82]  H. Moses,et al.  Induction by transforming growth factor-β1 of epithelial to mesenchymal transition is a rare event in vitro , 2004, Breast Cancer Research.

[83]  M. Owen,et al.  Evidence that metformin exerts its anti-diabetic effects through inhibition of complex 1 of the mitochondrial respiratory chain. , 2000, The Biochemical journal.

[84]  M. Rigoulet,et al.  Dimethylbiguanide Inhibits Cell Respiration via an Indirect Effect Targeted on the Respiratory Chain Complex I* , 2000, The Journal of Biological Chemistry.

[85]  Y. Tsujimoto,et al.  ATP-dependent steps in apoptotic signal transduction. , 1999, Cancer research.

[86]  Y. Tsujimoto,et al.  Intracellular ATP levels determine cell death fate by apoptosis or necrosis. , 1997, Cancer research.